Origin

Synthesized by the St. Petersburg Institute of Bioregulation and Gerontology in the Khavinson organ-targeted bioregulator tradition, on the premise that short synthetic peptides can selectively influence specific tissues through epigenetic mechanisms.

Mechanism

Proposed to activate cartilage cell proliferation and differentiation by interacting with DNA promoter regions in cartilage-specific genes, regulating chondrogenic markers and extracellular matrix proteins.

Research summary

Evidence

No English-language peer-reviewed studies indexed in PubMed exist for Cartalax specifically. It's referenced only in Russian-language literature and commercial or community sources, unreplicated in Western academic literature. Evidence quality here is the lowest tier in the family.

Evidence tier: Approved in Russia; research compound — see the methodology note for how this is assessed.

Citations

No specific peer-reviewed citations indexed for this entry — see the research summary above for what evidence does exist.

Reported benefits

claimed joint cartilage regeneration
claimed improved cartilage cell proliferation
claimed reduced joint degeneration

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Subcutaneous injection	Community reports: 10-20 mg daily or every other day for 10-20 days, repeated after 3-6 months.

Side effects

localized injection-site reactions when injected

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Community reports suggest positive effects on joint pain and mobility, entirely anecdotal. Typically sourced through import from Russia.